Ralometostat
Small molecule
Also known as TNG908
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
The company announced it stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization, and later referenced the discontinuation of the TNG908 clinical program. Company Form 10-Q; approved in the freshness review queue. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05275478 NCT05275478 · Locally Advanced Solid Tumor Registry: NCT05275478 | 1/2 | Phase 1: (28 days); Phase 2: (16 weeks) 2025-12-30 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other PRMT5 drugs
AZD3470, BAY 3713372, TNG456, Vopimetostat, HSK41959 and 1 more. Compare all 7 PRMT5 drugs
6 other tracked programmes target this mechanism, 6 of them ahead of this one.
This drug's own stage for Glioblastoma: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ralometostat: this drug | Discontinued | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Phase 3 | Small molecule | PARP1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD3470 | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BAY 3713372 | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Temferon | Phase 1/2 | Gene therapy / editing | Interferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cells | not yet graded | No reviewed efficacy summary in this indication | |
| TNG456 | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| Vopimetostat | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zedoresertib | Phase 1/2 | Small molecule | WEE1 kinase | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1390 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| HSK41959 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IDE892 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.